Which of the following statements is/are correct with reference to the Covishield?
A. Covishield is Serum Institute of India’s version of AZD1222.
B. The vaccine developed by AstraZeneca in collaboration with the University of Oxford.
C. Both A & B
D. None of these
Explanation:
The implementation of a Central advisory to extend the interval for injecting the second dose of Covishield vaccines to between six to eight weeks of the first jab will cover a significant proportion of the vaccinated population. Covishield is Serum Institute of India’s version of AZD1222, the vaccine developed by AstraZeneca in collaboration with the University of Oxford.